Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
|
|
- Isabella Shelton
- 5 years ago
- Views:
Transcription
1 The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product. Before prescribing any product mentioned in this Register, healthcare professionals should consult prescribing information for the product approved in their country. Study No.: WELL AK Title: A multicenter, double-blind, placebo-controlled comparison of the efficacy and safety of flexible dose extendedrelease bupropion hydrochloride (HCl) mg/day and placebo administered for eight weeks for the treatment of adult outpatients with major depressive disorder including symptoms of decreased energy, pleasure, and interest. Rationale: The purpose of this study was to evaluate the efficacy and safety of extended-release bupropion () versus placebo () in the treatment of subjects with a diagnosis of major depressive disorder including symptoms of decreased energy, pleasure, and interest, and to determine the effect of versus on this symptom triad. Phase: IIIB/IV Study Period: 24 June 2003 to 30 June 2004 Study Design: This was a multicenter, double-blind, randomized, parallel-group, -controlled study. Centers: 24 centers in the United States Indication: Major Depressive Disorder Treatment: Following a screening phase, subjects were enrolled in an 8-week treatment phase and received or matching placebo tablets. Subjects randomized to received 150mg/day for approximately 1 week and then their dose was uptitrated to 300mg/day. Subjects remained on 300mg/day for 3 weeks. If clinically indicated (i.e., additional efficacy was desired and the subject tolerated the current dose) the dose of could be increased to 450mg/day at Week 4. Any subject unable to tolerate 450mg/day was allowed to decrease their dose to 300mg/day for the duration of the study. Subjects unable to tolerate 300mg/day were allowed to decrease their dose to 150mg/day once during the study; subjects were then required to increase their dose back to 300mg/day after 1-2 weeks. If these subjects were unable to tolerate 300mg/day, they were to be discontinued from the study. Objectives: The primary objective of this study was to compare the effectiveness of versus in the treatment of adult outpatients with major depressive disorder including symptoms of decreased energy, pleasure, and interest as measured by the Inventory of Depressive Symptomatology-Self Report (IDS-SR). Primary Outcome/Efficacy Variable: The primary efficacy endpoint was the mean change from baseline (randomization) to Week 8/Study Exit in the IDS-SR total score. Secondary Outcome/Efficacy Variable(s): Secondary efficacy endpoints were the: (1) mean change from baseline to Week 8/Study Exit in the Inventory of Depressive Symptomatology-Clinician Rated (IDS-C) total score; (2) mean change from baseline to Week 8/Study Exit in the 5-item (Items 19, 20, 21, 22, and 30) subscale score of the IDS-SR assessing energy, pleasure, and interest; (3) percentage of IDS-SR responders (subjects with a reduction in IDS-SR total score of 50% from baseline) at Week 8/Study Exit); (4) percentage of IDS-SR remitters (subjects whose IDS- SR total score was 15) at Week 8/Study Exit; (5) percentage of Clinical Global Impression Improvement (CGI-I) responders (subjects with a score of much or very much improved on the CGI-I) at each study visit; (6) mean change from baseline to Week 8/Study Exit in the Clinical Global Impression Severity of Illness (CGI-S) total score; (7) percentage of Patient Global Impression Improvement (PGI-I) responders (subjects with a score of much or very much improved on the PGI-I) at each study visit); (8) mean change from baseline to Week 8/Study Exit in the Patient Global Impression Severity of Illness (PGI-S) total score; (9) mean change from baseline to Week 8/Study Exit in the 3-item (Items 1, 2, and 3) subscale score of the IDS-SR assessing insomnia. Health Outcome Variable(s): Health outcomes were assessed by the: (1) mean change from baseline to Week 8/Study Exit in the Quality of Life Enjoyment and Satisfaction Questionnaire Short-Form (Q-LES-Q-SF) General Activities Scale score; (2) mean change from baseline to Week 8/Study Exit in the Q-LES-Q-SF Life Satisfaction and Contentment Scale Score; (3) mean change from baseline to Week 8/Study Exit in the Motivation and Energy Inventory (MEI) total score; and (4) baseline and Week 8/Study Exits Q-LES-Q-SF Satisfaction with Medication questionnaire. Statistical Methods: Two populations were defined for the study: (1) the safety population, which consisted of any randomized subject who took at least one dose of study drug; and (2) the intent-to-treat (ITT) population, which consisted of all randomized subjects who took at least one dose of study drug and provided a baseline (Day 1) IDS- SR assessment and at least one IDS-SR assessment post-baseline. All efficacy analyses and all health outcome analyses were conducted using the ITT population. Treatment comparisons were primarily made using lastobservation-carried-forward (LOCF) values. Continuous endpoints were analyzed using analysis of covariance (ANCOVA) with center and treatment as fixed factors and value at baseline (randomization) visit as the continuous
2 covariate. Categorical endpoints were analyzed using Cochran-Mantel-Haenszel test controlling for center. Consistent with the fact that is a known antidepressant, the alternative hypothesis that was better than was tested, and one-sided p-values were calculated. [Note: The mean change from baseline in PGI-S score was not analyzed because PGI-S data were inadvertently not collected at Week 8/Study Exit.] Mean change from baseline in the IDS-SR total score, IDS-C total score, and 5-item energy, pleasure, and interest subscale score of the IDS-SR at Week 8/Study Exit were analyzed using one-sided p-values unadjusted for multiplicity. For secondary endpoints (3) through (9) in the Secondary Outcome/Efficacy Variable(s) section above, endpoints unadjusted and adjusted one-sided p-values (Hochberg) were compiled. Study Population: Male or female subjects of at least 18 years of age were eligible for this study if he/she had: (1) a primary diagnosis of major depressive disorder as defined by the Diagnostic and Statistical Manual of Mental Disorders (4 th Edition)(DMS-IV) criteria and determined by a psychiatric interview that included the Mini International Neuropsychiatric Interview (MINI); (2) a minimum score of 25 on the IDS-SR when measured at screen (Day 7) and at baseline/randomization (Day 1); (3) scores of at least 1 on 4 out of 5 items on the 5-item subscale of the IDS-SR and a total score of at least 7 on the 5-item subscale of the IDS-SR at screening and baseline; and (4) a duration of current depressive episode of at least 12 weeks but no greater than 2 years and met all other inclusion/exclusion criteria. Number of Subjects: Planned, N Enrolled/Randomized, N Safety Population ITT Population Completed, n (% Randomized) 103 (76.3) 110 (79.1) Total Number of Subjects Withdrawn, n (% Randomized) 32 (23.7) 29 (20.9) Withdrawn due to AEs, n (% Randomized) 12 (8.9) 3 (2.2) Withdrawn due to Lack of Efficacy, n (% Randomized) 1 (0.7) 6 (4.3) Withdrawn for Other Reasons, n (% Randomized) 19 (14.1) 20 (14.4) Demographics: (Safety Population) Females: Males 89:46 96:43 Mean Age, years (sd) 40.0 (12.2) 39.8 (11.9) White, 104 (77.0) 108 (77.7) Primary Efficacy Results: ITT Population N= N= Exit in IDS-SR Total Score (LOCF) Baseline Score Mean, 45.9 (0.8) 46.0 (0.8) (1.4) (1.4) p-value Secondary Efficacy Results: (ITT Population) N= N= Exit in IDS-C Total Score (LOCF) Baseline Score Mean, 44.5 (0.7) 43.9 (0.7) (1.3) (1.3) Exit in 5-Item IDS-SR Energy, Pleasure, and Interest Subscale Score (LOCF) Baseline Score Mean, 11.6 (0.2) 11.9 (0.2) -6.7 (0.4) -5.3 (0.4) Percentage of IDS-SR Responders ( 50% reduction in IDS-SR Total Score from Baseline at Week 8/Study Exit) (LOCF) 71 (53.4) 61 (44.5) Percentage of IDS-SR Remitters (IDS-SR Total Score of 15 at
3 Week 8/Study Exit (LOCF) 54 (40.6) 37 (27.0) Percentage of CGI-I Responders (Score of much or very much improved from Baseline) at each Study Visit (LOCF) N= N= Week 1, n 20 (15.2) 6 (4.4) Week 2, n 41 (31.1) 24 (17.6) Week 4, n 58 (43.6) 42 (30.9) Week 6, n 68 (51.1) 47 (34.6) 70 (52.6) 51 (37.5) Exit in CGI-S Total Score (LOCF) Baseline Score Mean, 4.6 (0.1) 4.6 (0.1) -1.5 (0.1) -1.1 (0.1) Percentage of PGI-I Responders (Score of much or very much improved from Baseline) at each Study Visit (LOCF) Week 1, n (6.1) 2 (1.5) Week 2, n 24 (18.2) 15 (10.9) Week 4, n 42 (31.6) 30 (21.9) Week 6, n 58 (43.6) 40 (29.2) 59 (44.4) 50 (36.5) Exit in PGI_S Total Score (LOCF) Baseline Score Mean, Not Available (NA) NA NA NA Exit in 3-Item IDS-SR Insomnia Subscale Score (LOCF) Baseline Score Mean, 5.9 (0.2) 5.7 (0.2) -2.1 (0.2) -1.5 (0.2) 32.9 (0.9) 32.5 (1.0) Exit in Q-LES-Q-SF General Activities Scale Score (LOCF) Baseline Score Mean, 21.5 (1.8) 15.2 (1.8) 2.0 (0.1) 1.9 (0.1) Exit in Q-LES-Q-SF Life Satisfaction and Contentment Score (LOCF) Baseline Score Mean, 1.2 (0.1) 0.8 (0.1) 22.6 (1.0) 22.3 (1.0) Exit in MEI Total Score (LOCF) Baseline Score Mean, 24.5 (2.0) 17.4 (2.0)
4 Percentage of Subjects Taking Medication and Satisfied with Medication at Baseline and at Week 8/Study Exit (Randomized Population) Baseline, n Taking Medications Baseline Satisfaction Level, n Very Good, Good Fair Poor Very Poor 31 (23.3) 29 (21.2) (9.7) 2 (6.9) 10 (32.3) 11 (37.9) 10 (32.3) 10 (34.5) 5 (16.1) 4 (13.8) 3 (9.7) 2 (6.9) 125 Taking Medications 63 (50.4) 74 (54.4) Week 8/Study Exit Satisfaction Level, n Very Good, 14 (22.2) 9 (12.2) Good 15 (23.8) 16 (21.6) Fair 19 (30.2) 24 (32.4) Poor 9 (14.3) 17 (23.0) Very Poor 6 (9.5) 8 (10.8) Safety Results: All safety analyses were conducted using the Safety Population. An AE was defined as any untoward medical occurrence in a patient or clinical investigation subject temporally associated with the use of medicinal product, whether or not considered related to the product. Most Frequent Adverse Events On-Therapy (Safety Population) Subjects with any AE(s), n(%) 106 (78.5) 85 (61.2) Headache 31 (23.0) 32 (23.0) Dry Mouth 17 (12.6) 8 (5.8) Constipation 15 (11.1) 11(7.9) Nausea 14 (10.4) 7 (5.0) Dizziness 14 (10.4) 3 (2.2) Insomnia 1 11 (8.1) 3 (2.2) Anxiety 8 (5.9) 1 (0.7) Dyspepsia 8 (5.9) 0 Sinusitis 7 (5.2) 3 (2.2) Tremor 7 (5.2) 0 Back Pain 6 (4.4) 5 (3.6) Decreased Appetite 6 (4.4) 4 (2.9) Palpitations 6 (4.4) 4 (2.9) Diarrhea 5 (3.7) 12 (8.6) Irritability 3 (2.2) 6 (4.3) Upper Respiratory Tract Infection 5 (3.7) 5 (3.6) Upper Abdominal Pain 5 (3.7) 4 (2.9) Fatigue 2 (1.5) 4 (2.9) Myalgia 2 (1.5) 4 (2.9) Flatulence 0 4 (2.9) 1 Includes insomnia, initial insomnia, middle insomnia and early morning awakening Serious Adverse Events On Therapy (Safety Population) [n considered by the investigator to be related to study medication] Subjects with non-fatal SAE(s), n(%) 0 0 Subjects with fatal SAE(s), n(%) 0 0
5 Conclusion: See publication below. Publications: Rush J, VanMeter SA, Wightman D, Hampton KD, Krishen A, Modell JG. Wellbutrin XL for the treatment of adults with major depressive disorder. American Psychiatric Association 158 th Annual Meeting, Atlanta, GA, May, 2005, Abstract No Rush J, VanMeter SA, Wightman DS, Hampton KD, Krishen A, Modell JG. Bupropion XL for the treatment of adults with major depressive disorder. 45 th Annual New Clinical Drug Evaluation Unit (NCDEU) Meeting, Boca Raton, FL, 6-9 June, Jefferson JW, Rush AJ, Nelson JC, VanMeter SA, Krishen A, Hampton KD, Wightman DS, Modell JG. Extendedrelease bupropion for major depressive disorder with symptoms of reduced energy, pleasure, and interest: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry, 2006; 67: Date Updated: 14-Jun-2007
Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
Study No.: 29060/717 Title: A Double-Blind, Placebo-Controlled, 3-Arm, Fixed-Dose Study of CR Intermittent Dosing (12.5 mg and 25 mg) for Premenstrual Dysphoric Disorder Rationale: In most trials investigating
More informationStudy No.:MPX Title: Rationale: Phase: IIB Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objective: Primary Outcome/Efficacy Variable:
Studies listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objective: Primary Outcome/Efficacy Variable:
Studies listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSummary ID#7029. Clinical Study Summary: Study F1D-MC-HGKQ
CT Registry ID# 7029 Page 1 Summary ID#7029 Clinical Study Summary: Study F1D-MC-HGKQ Clinical Study Report: Versus Divalproex and Placebo in the Treatment of Mild to Moderate Mania Associated with Bipolar
More informationStudy No: Title: Rationale: . Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationBRL /RSD-101C0D/1/CPMS-704. Report Synopsis
Report Synopsis Study Title: A Randomized, Multicenter, 10-Week, Double-Blind, Placebo- Controlled, Flexible-Dose Study to Evaluate the Efficacy and Safety of Paroxetine in Children and Adolescents with
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable(s):
Studies listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationThis was a randomized, double-blind, placebo-controlled, fixed-dose, parallel-group study.
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See United States Package Insert (USPI)
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationStudy Center(s): The study was conducted at 39 study sites in Japan.
SYNOPSIS Issue Date: 20 NOVEMBER 2012 Name of Sponsor/Company Janssen Pharmaceutical K. K. Name of Finished Product CONCERTA Name of Active Ingredient(s) Methylphenidate HCl Protocol No.: JNS001-JPN-A01
More informationSponsor. Novartis Pharmaceuticals Corporation Generic Drug Name. Agomelatine Therapeutic Area of Trial. Major depressive disorder Approved Indication
Clinical Trial Results Database Page 1 Sponsor Novartis Pharmaceuticals Corporation Generic Drug Name Therapeutic Area of Trial Major depressive disorder Approved Indication Investigational drug Study
More informationSummary ID# Clinical Study Summary: Study B4Z-MC-LYBX
CT Registry ID#7068 Page 1 Summary ID# 7068 Clinical Study Summary: Study B4Z-MC-LYBX A Randomized, Double-Blind Comparison of Hydrochloride and Placebo in Child and Adolescent Outpatients with Attention-
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSYNOPSIS 2/198 CSR_BDY-EFC5825-EN-E02. Name of company: TABULAR FORMAT (For National Authority Use only)
SYNOPSIS Title of the study: A randomized, double-blind, placebo-controlled, parallel-group, fixed-dose (rimonabant 20 mg) multicenter study of long-term glycemic control with rimonabant in treatment-naïve
More informationStudy No: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More information(+)-3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-ethyl]- 6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4H-pyridol[1,2-a]pyrimidin-4- one
SYNOPSIS Issue Date: 18 November 2008 Document No.: EDMS-PSDB-9006510:2.0 Name of Sponsor/Company Name of Finished Product Name of Active Ingredient(s) Ortho-McNeil Janssen Scientific Affairs, L.L.C. Paliperidone
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationSYNOPSIS. Risperidone-R064766: Clinical Study Report RIS-USA-232 (FOR NATIONAL AUTHORITY USE ONLY)
SYNOPSIS Protocol No.: RIS-USA-232 Title of Study: Efficacy and Safety of a Flexible Dose of Risperidone Versus Placebo in the Treatment of Psychosis of Alzheimer's Disease Principal Investigator: M.D.
More informationAllergan Not Applicable AGN A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Multiple Dose, Parallel
Peripheral Neuropathy Design, Dose Ranging Study of the Safety and Efficacy of AGN 203818 in Patients with Painful Diabetic 203818-004. A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Multiple
More informationHM2008/00566/00. study and to obtain clinical experience with the use of this drug. Primary Outcome/Efficacy Variable(s): <Pharmacokinetics>
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationClinical Trial Results Database Page 1
Clinical Trial Results Database Page 1 Sponsor Novartis Pharmaceuticals Corporation Generic Drug Name Therapeutic Area of Trial Major Depressive Disorder (MDD) Approved Indication Treatment of major depressive
More informationSYNOPSIS (FOR NATIONAL AUTHORITY USE ONLY) INDIVIDUAL STUDY TABLE REFERRING TO PART OF THE DOSSIER
SYNOPSIS Protocol No.: RIS-USA-63 Psychosis in Alzheimer s disease (PAD) analysis Title of Study: A randomized, double-blind, placebo controlled study of risperidone for treatment of behavioral disturbances
More informationSummary ID# Clinical Study Summary: Study B4Z-MC-LYCL
CT Registry ID#8226 Page 1 Summary ID# 8226. Clinical Study Summary: Study B4Z-MC-LYCL Guiding Dose Increases in Patients Incompletely Responsive to Usual Doses of Atomoxetine by Determining Plasma Atomoxetine
More informationBRL /RSD-101RLL/1/CPMS-716. Report Synopsis
Report Synopsis Study Title: A Multicenter, Open-label, Six-Month Extension Study to Assess the Long-term Safety of Paroxetine in Children and Adolescents with Major Depressive Disorder (MDD) or Obsessive-Compulsive
More informationSummary ID#236 Clinical Study Summary: Study B1Y-MC-HCCJ
CT Registry ID#236 Page 1 Summary ID#236 Clinical Study Summary: Study B1Y-MC-HCCJ Title of Study: Fluoxetine: Fluoxetine versus Placebo in Adolescent Depressed Patients Investigator(s): This single-center
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis
More informationPaliperidone: Clinical Protocol R076477SCH4012, CR Amendment INT-1
Paliperidone: Clinical Protocol R076477SCH4012, CR013771 Amendment INT-1 A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of a Fixed
More informationUMEC/VI vs. UMEC in subjects who responded to UMEC UMEC/VI vs. VI in subjects who responded to VI
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSYNOPSIS. Risperidone-R064766: Clinical Study Report RIS-INT-24 (FOR NATIONAL AUTHORITY USE ONLY)
SYNOPSIS Protocol No.: RIS-INT-24 Psychosis in Alzheimer s disease (PAD) analysis Title of Study: Risperidone in the treatment of behavioral disturbances in demented patients: an international, multicenter,
More informationSYNOPSIS. Risperidone-R064766: Clinical Study Report RIS-AUS-5 (FOR NATIONAL AUTHORITY USE ONLY)
SYNOPSIS Protocol No.: RIS-AUS-5 Psychosis in Alzheimer s disease (PAD) analysis Title of Study: Risperidone in the treatment of behavioral and psychological symptoms in dementia: a multicenter, double-blind,
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: This drug is not marketed in the United States.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationIndividual Study Table Referring to Part of the Dossier. Volume: Page:
1 SYNOPSIS (CR002878) Title of Study: The effect of on vasomotor symptoms in healthy postmenopausal women: a double-blind placebo controlled pilot study Investigators: Multiple, see Section 4, Investigators
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Co-Primary Outcomes/Efficacy Variables:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSYNOPSIS. Study center(s) This study was conducted in the United States (128 centers).
Drug product: Drug substance(s): Document No.: Edition No.: Study code: Date: SYMBICORT pmdi 160/4.5 µg Budesonide/formoterol SD-039-0725 17 February 2005 SYNOPSIS A Twelve-Week, Randomized, Double-blind,
More informationPrevious Study Return to List Next Study
A service of the U.S. National Institutes of Health Trial record 1 of 1 for: 42603ATT3013 Previous Study Return to List Next Study A Study to Evaluate Effectiveness and Safety of Prolonged Release OROS
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationSupplementary Online Content
Supplementary Online Content Daly EJ, Singh JB, Fedgchin M, et al. Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: a randomized
More informationThe study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationBRL /RSD-101C0F/1/CPMS-716. Report Synopsis
Report Synopsis Study Title: A Multicenter, Open-label, Six-Month Extension Study to Assess the Long-Term Safety of Paroxetine in Children and Adolescents with Major Depressive Disorder (MDD) or Obsessive-Compulsive
More informationSummary ID# Clinical Study Summary: Study B4Z-MC-LYBU
CT Registry ID#7065 Page 1 Summary ID# 7065 Clinical Study Summary: Study B4Z-MC-LYBU A Randomized, Double-Blind Comparison of Atomoxetine Hydrochloride Augmented with Either Extended-Release Methylphenidate
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More information2. SYNOPSIS Name of Sponsor/Company:
in patients with refractory partial seizures 14 Jun 2007 2. SYNOPSIS TITLE OF STUDY: Efficacy and safety of BIA 2-093 as adjunctive therapy for refractory partial seizures in a double-blind, randomized,
More informationStudy No.: Title: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSummary ID# Clinical Study Summary: Study F1J-MC-HMDV
CT Registry ID# 7108 Page 1 Summary ID# 7108 Clinical Study Summary: Study F1J-MC-HMDV Duloxetine 60 to 120 mg Once Daily Compared with Placebo in the Prevention of Relapse in Generalized Anxiety Disorder
More informationCLINICAL STUDY REPORT SYNOPSIS
CLINICAL STUDY REPORT SYNOPSIS Document No.: EDMS-PSDB-6511694:4.0 Name of Sponsor/Company Johnson & Johnson Pharmaceutical Research & Development Name of Finished Product Name of Active Ingredient Protocol
More informationPFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. PROPRIETARY DRUG NAME /GENERIC DRUG NAME: Effexor XR /
More informationThe study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSYNOPSIS. ER OROS Paliperidone: Clinical Study Report R SCH-301
SYNOPSIS Protocol No.: R076477-SCH-301 Title of Study: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With an Open-Label Extension Evaluating Extended Release OROS Paliperidone in
More informationmg 25 mg mg 25 mg mg 100 mg 1
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSYNOPSIS INDIVIDUAL STUDY TABLE REFERRING TO PART OF THE DOSSIER (FOR NATIONAL AUTHORITY USE ONLY) Volume: Page:
SYNOPSIS Risperdal Risperidone (R064766) Protocol No.: RIS-USA-150 Part 1 INDIVIDUAL STUDY TABLE REFERRING TO PART OF THE DOSSIER AUTHORITY USE ONLY) Title of Study: A Double-Blind, Placebo-Controlled
More informationSYNOPSIS. Study Coordinator. Study centre(s)
Drug product: Seroquel Drug substance(s): Quetiapine Document No.: 1 Edition No.: 1 Study code: D1449C00005 Date: 02 January 2007 SYNOPSIS A Randomized, Parallel Group, Open Trial Examining the Safety,
More informationSecondary Outcome/Efficacy Variable(s):
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More information2.0 Synopsis. ABT-711 M Clinical Study Report R&D/06/054. (For National Authority Use Only) Referring to Part of Dossier: Volume: Page:
2.0 Synopsis Abbott Laboratories Name of Study Drug: Depakote ER Name of Active Ingredient: Divalproex Sodium Individual Study Table Referring to Part of Dossier: Volume: Page: (For National Authority
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationThe study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: LOV Title: Rationale: Phase: IIB Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary-
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationClinical Trial Results Summary Study EN3409-BUP-305
Title of Study: A 52-Week, Open-Label, Long-Term Treatment Evaluation of the Safety and Efficacy of BEMA Buprenorphine in Subjects with Moderate to Severe Chronic Pain Coordinating Investigator: Martin
More informationClinical Trial Synopsis
Clinical Trial Synopsis Title of Study: A Phase III, Open-Label, Fixed-Dose Study to Determine the Safety of Long-Term Administration of TAK-375 in Subjects With Chronic Insomnia Protocol Number: Name
More informationSummary ID# Clinical Study Summary: Study B4Z-JE-LYBC
CT Registry ID# 5285 Page 1 Summary ID# 5285 Clinical Study Summary: Study B4Z-JE-LYBC A Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Comparison of Fixed-Dose Ranges of Hydrochloride
More informationSponsor / Company: Sanofi Drug substance(s): AMARYL M (1/250 mg) / HOE490
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationPregabalin As A Treatment for Generalized Anxiety Disorder. Ashley Storrs PGY III December 2, 2010
Pregabalin As A Treatment for Generalized Anxiety Disorder Ashley Storrs PGY III December 2, 2010 Background Information Approximately 18.1 percent of American adults 18 years or older have an anxiety
More informationPFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. PROPRIETARY DRUG NAME / GENERIC DRUG NAME: Advil / Ibuprofen
More informationClinical Trial Synopsis TL-OPI-518, NCT#
Clinical Trial Synopsis, NCT# 00225264 Title of Study: A Double-Blind, Randomized, Comparator-Controlled Study in Subjects With Type 2 Diabetes Mellitus Comparing the Effects of Pioglitazone HCl vs Glimepiride
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objective: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationMedicinal product no longer authorised SCIENTIFIC DISCUSSION. London, 22 November 2007 Product Name : Ariclaim Procedure No: EMEA/H/C/000552/II/0024
European Medicines Agency Post-Authorisation Evaluation of Medicines for Human Use London, 22 November 2007 Product Name : Ariclaim Procedure No: EMEA/H/C/000552/II/0024 SCIENTIFIC DISCUSSION 1/7 EMEA
More informationH6D-MC-LVHR Clinical Study Report Synopsis Page LVHR Synopsis (LY450190)
H6D-MC-LVHR Clinical Study Report Synopsis Page 1 2. LVHR Synopsis H6D-MC-LVHR Clinical Study Report Synopsis Page 2 Clinical Study Report Synopsis: Study H6D-MC-LVHR Title of Study: A Randomized, Double-Blind,
More informationHydrocodone/Acetaminophen Extended-Release Tablets M Clinical Study Report R&D/09/1109
2.0 Synopsis Abbott Laboratories Individual Study Table Referring to Part of Dossier: (For National Authority Use Only) Name of Study Drug: ABT-712 Volume: Hydrocodone/Acetaminophen Extended-Release Name
More informationABC/3TC/ZDV ABC PBO/3TC/ZDV
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationTrial No.: RIS-USA-102 Clinical phase: III
SYNOPSIS Trial identification and protocol summary Company: Johnson & Johnson Pharmaceutical Research and Development, a division of Janssen Pharmaceutica, N.V. Finished product: Risperdal Active ingredient:
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationINDIVIDUAL STUDY TABLE REFERRING TO PART OF THE DOSSIER Volume: Page:
SYNOPSIS Protocol No.: CR004357 Title of Study: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of 50 and 100 mg eq. of Paliperidone Palmitate in Subjects With
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: ADF Title: Phase III study of adefovir dipivoxil (ADV) tablets in patients with compensated chronic hepatitis B -comparative study
Study No.: ADF105220 Title: Phase III study of adefovir dipivoxil () tablets in patients with compensated chronic hepatitis B -comparative study against lamivudine ()- Rationale: This study wass a confirmatory
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationJanssen-Cilag EMEA Medical Affairs a division of Janssen Pharmaceuticals N.V.
SYNOPSIS Issue Date: Final 22 July 2009 [Document No.: EDMS-PSDB-9245102] Name of Sponsor/Company Name of Finished Product Risperdal Consta Name of Active Ingredient(s) Protocol No.: RIS-BMN-3001 Janssen-Cilag
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objective:
GSK Medicine: abacavir (ABC)/dolutegravir (DTG)/lamivudine (3TC) Study Number: 201147 Title: A IIIb, randomized, open-label study of the safety, efficacy, and tolerability of switching to a fixed-dose
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No. 178-CL-008 Report Final Version, 14 Dec 2006 Reissued Version, 18 Jul 2011 Astellas Pharma Europe B.V. Page 13 of 122
Page 13 of 122 3 SYNOPSIS Title of study: (International) Study No: A randomized, double-blind, parallel group, proof-of-concept study of in comparison with placebo and tolterodine in patients with symptomatic
More informationSupplementary Online Content
Supplementary Online Content Janssen CW, Lowry CA, Mehl MR, et al. Whole-body hyperthermia for the treatment of major depressive disorder: a randomized clinical trial. JAMA Psychiatry. Published online
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationPFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. PROPRIETARY DRUG NAME / GENERIC DRUG NAME: Lyrica / Pregabalin
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationTitle of Study: Evaluation of Efficacy and Safety of Galantamine in Patients With Dementia of Alzheimer's Type Who Failed to Benefit From Donepezil
SYNOPSIS Name of Sponsor/Company Name of Finished Product REMINYL Name of Active Ingredient(s) Galantamine hydrobromide Issue Date: 18 October 2013 Protocol No.: Title of Study: Evaluation of Efficacy
More information